BBL
RPRX icon

Beck Bode LLC’s Royalty Pharma RPRX Stock Holding History

Beck Bode LLC’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-73,042
Closed -$2.05M – 136
2023
Q4 		$2.05M Buy
73,042
+464
+0.6% +$12.8K 0.46% 64
2023
Q3 		$1.97M Buy
72,578
+1,154
+2% +$34.3K 0.5% 64
2023
Q2 		$2.19M Buy
71,424
+985
+1% +$33.4K 0.53% 60
2023
Q1 		$2.54M Buy
+70,439
New +$2.61M 0.62% 55

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Beck Bode LLC's RPRX Position: Q1 2024 in Review

Beck Bode LLC sold out of Royalty Pharma (RPRX) in Q1 2024, closing a stake of 73,042 shares — an estimated $2.05M sold.

Beck Bode LLC first reported a position in RPRX in Q1 2023 and held it in 4 quarters. The position peaked at $2.54M in Q1 2023. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

  • Beck Bode LLC reported no remaining Royalty Pharma position as of Q1 2024 after selling out during the quarter.
  • Beck Bode LLC sold 73,042 Royalty Pharma shares in Q1 2024, an estimated $2.05M.
  • Beck Bode LLC first reported a position in Royalty Pharma in Q1 2023 and held it in 4 quarters.
  • Beck Bode LLC's Royalty Pharma position peaked at $2.54M in Q1 2023.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on Beck Bode LLC's 13F filing for Q1 2024, filed 22 May 2024.